IL5Tg (5 (link)), Arg1YFP (42 (link)), Il5Red5Cre (Red5) (10 (link)), ILC2-deleted (ILC2del) (10 (link)); STAT6–/– (43 (link)), Smart13 (35 (link)), IL4Rα–/– (44 (link)), and IL4–/–/IL13–/– (45 (link)) mice have been described. Mice were derived or backcrossed on a C57BL/6J background for more than 10 generations, and housed under specific pathogen–free conditions with 12-hr light/day cycles and ad libitum access to food and water. Experiments were performed on age- and sex-matched male and female mice between 8 weeks and 16 weeks of age, except for the eotaxin experiments, in which mice were 6 months of age. IL-33 (BioLegend or R&D), TSLP (eBioscience), or IL-25 (R&D) were administered intranasally at 0.5 μg per dose, 3 times a week for 2 weeks, and mice were analyzed 1 day after the final dose. For intravascular labeling experiments, mice were injected intravenously with 3 μg of anti-mouse CD45 Ab (clone 30-F11) 3 minutes prior to sacrifice. Eotaxin was measured from serum using the Mouse CCL11/Eotaxin Quantikine ELISA Kit (R&D).
Free full text: Click here